- Home
- INBX vs ELDN Comparison
INBX vs ELDN Comparison
Compare INBX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- ELDN
- Stock Information
- Founded
- INBX 2010
- ELDN 2004
- Country
- INBX United States
- ELDN United States
- Employees
- INBX N/A
- ELDN N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- ELDN Health Care
- Exchange
- INBX Nasdaq
- ELDN Nasdaq
- Market Cap
- INBX 168.1M
- ELDN 178.4M
- IPO Year
- INBX 2020
- ELDN N/A
- Fundamental
- Price
- INBX $11.86
- ELDN $3.36
- Analyst Decision
- INBX Hold
- ELDN Strong Buy
- Analyst Count
- INBX 1
- ELDN 1
- Target Price
- INBX N/A
- ELDN $16.00
- AVG Volume (30 Days)
- INBX 142.0K
- ELDN 235.0K
- Earning Date
- INBX 05-08-2025
- ELDN 05-08-2025
- Dividend Yield
- INBX 7.26%
- ELDN N/A
- EPS Growth
- INBX N/A
- ELDN N/A
- EPS
- INBX 112.62
- ELDN N/A
- Revenue
- INBX $200,000.00
- ELDN N/A
- Revenue This Year
- INBX N/A
- ELDN N/A
- Revenue Next Year
- INBX N/A
- ELDN N/A
- P/E Ratio
- INBX $0.10
- ELDN N/A
- Revenue Growth
- INBX N/A
- ELDN N/A
- 52 Week Low
- INBX $10.80
- ELDN $1.91
- 52 Week High
- INBX $18.95
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- INBX 41.57
- ELDN 38.72
- Support Level
- INBX $11.22
- ELDN $2.63
- Resistance Level
- INBX $12.06
- ELDN $3.21
- Average True Range (ATR)
- INBX 0.95
- ELDN 0.24
- MACD
- INBX -0.11
- ELDN 0.03
- Stochastic Oscillator
- INBX 32.99
- ELDN 46.84
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.